Michael S Kuhns

Title: Michael S. Kuhns: Innovator in Immunotherapy

Introduction

Michael S. Kuhns is a notable inventor based in Tucson, Arizona. He has made significant contributions to the field of immunotherapy through his innovative work on chimeric receptors. His research focuses on redirecting cells to enhance their specificity in targeting diseases.

Latest Patents

Kuhns holds a patent titled "Redirected cells with MHC chimeric receptors and methods of use in immunotherapy." This patent involves chimeric receptors that feature major histocompatibility molecules grafted onto T cell receptor molecules. Additionally, it includes surrogate co-receptors that consist of cell surface receptor ligands fused with signaling molecule domains. The chimeric receptors can be utilized to redirect cells, altering their specificity. T cells expressing these chimeric receptors may bind to immune checkpoint receptors (ICRs) of target T cells for which their chimeric receptors are specific. Surrogate co-receptors can enhance TCR-CD3 signaling as part of this modular receptor system. This innovative approach may help eliminate autoreactive T cells or program T cells to achieve desired effector functions. Kuhns has 1 patent to his name.

Career Highlights

Throughout his career, Kuhns has worked with esteemed organizations, including the Arizona Board of Regents on Behalf of the University of Arizona and Joslin Diabetes Center, Inc. His work has significantly impacted the development of immunotherapeutic strategies.

Collaborations

Kuhns has collaborated with Thomas Serwold, contributing to advancements in the field of immunotherapy.

Conclusion

Michael S. Kuhns is a pioneering inventor whose work in immunotherapy has the potential to transform treatment approaches for various diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.